NLRP3 inflammasome

Targeting IL-17A-Driven PTGS2/NLRP3 Inflammasome Activation: A Novel Therapeutic Approach in PTPN11-Mutant Juvenile Myelomonocytic Leukemia

By MedXY 09/22/2026

This study identifies an IL-17A/PTGS2/NLRP3 signaling axis as a key driver of immune suppression and myeloproliferation in PTPN11-mutant JMML, demonstrating that combined inflammasome and PTGS2 inhibition with MEK blockade improves survival and reduces leukemic burden.

Cardiology Internal Medicine news

Oral NLRP3 Inhibition With Ruvonoflast Produces Rapid, Reversible Suppression of Residual Inflammation in Adults at High Cardiovascular Risk

By MedXY 06/10/2026

In a Phase 1b placebo-controlled trial, ruvonoflast markedly reduced hsCRP, IL-6, and fibrinogen over 28 days in adults with obesity, elevated hsCRP, and cardiometabolic risk, supporting further evaluation of oral NLRP3 inhibition in atherosclerotic prevention.

news Otorhinolaryngology

NLRP3 Inflammasome in Hearing Loss: Mechanisms and Emerging Therapeutic Strategies

By MedXY 11/04/2025

The NLRP3 inflammasome plays a central role in inflammation-mediated sensorineural hearing loss (SNHL). Genetic and acquired activation causes cochlear damage through cytokine release and pyroptosis. Targeted therapies, including IL-1 blockers and novel NLRP3 inhibitors, offer hope for effective treatment of various SNHL forms.

Clinical Updates Neurology Specialties

NLRP3 Inflammasome and Gut Microbiota-Brain Axis: Emerging Insights into White Matter Injury After Intracerebral Hemorrhage

By MedXY 09/29/2025

This article explores how gut microbiota dysbiosis and NLRP3 inflammasome activation contribute to secondary white matter injury post-intracerebral hemorrhage, outlining mechanisms and potential therapeutic strategies.